SCHEMBL535519

SCHEMBL535519

Nc1c(Br)cc(Cl)nc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.43
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
KMO O15229 1/20 0.36
GSK3B P49841 1/20 0.35
ALDH1A1 P00352 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
S1PR2 O95136 1/20 0.33
MCL1 Q07820 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
LMNA P02545 1/20 0.33
GRIK1 P39086 1/20 0.33
GRIA1 P42261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30609423 0.85 LMNA (0.38) GAAMAPTGSK3BCA1CA2
SCHEMBL22715659 0.84 KMT2A (0.36) TDP1GAAMAPTGSK3BALDH1A1
SCHEMBL536122 0.81 TDP1 (0.46) TDP1MAPTKMOALDH1A1MAPK1
SCHEMBL535508 0.81 TDP1 (0.37) TDP1GAAMAPTKMOGSK3B
SCHEMBL25359313 0.80 CFTR (0.44) GAAMAPTCA9KMT2AS1PR2
SCHEMBL31330704 0.80 NPSR1 (0.42) GAAALDH1A1SMN1; SMN2HSD17B10KDM4E
SCHEMBL535659 0.80 NPSR1 (0.42) GAAALDH1A1SMN1; SMN2HSD17B10KDM4E
SCHEMBL536181 0.78 ALDH1A1 (0.46) TDP1KMOALDH1A1MAPK1SMN1; SMN2
SCHEMBL2342580 0.78 TDP1 (0.39) TDP1MAPTKMOALDH1A1MAPK1
SCHEMBL31437236 0.76 ALDH1A1 (0.43) GAAMAPTALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720061-A1 TREM2 AGONISTS F. Hoffmann-La Roche AG (CH) 2026-04-08 EP disclosed
WO-2025101598-A1 BI-CYCLIC PYRIMIDINE COMPOUNDS, METHODS AND USES THEREOF ZENO MANAGEMENT, INC. (US) 2025-05-15 WO disclosed
WO-2024246018-A1 TREM2 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2024-12-05 WO disclosed
US-20220204498-A1 PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2022-06-30 US disclosed
CN-113795307-A Pyridopyrimidinyl compounds and methods of use thereof 基因泰克公司 2021-12-14 CN disclosed
US-8247431-B2 Heterocyclic hydrazide compound and pesticidal use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-21 US disclosed
US-8247431-B2 Heterocyclic hydrazide compound and pesticidal use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-21 US disclosed
US-8247431-B2 Heterocyclic hydrazide compound and pesticidal use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-21 US disclosed
EP-2144898-B1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL CO (JP) 2012-02-08 EP disclosed
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 US disclosed
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 US disclosed
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 US disclosed
CN-101679377-A Heterocyclic hydrazide compound and pesticidal use of the same SUMITOMO CHEMICAL CO 2010-03-24 CN disclosed
EP-2144898-A2 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2010-01-20 EP disclosed
WO-2008130021-A2 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-10-30 WO disclosed
WO-2008130021-A2 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204498-A1 PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE XBP1, HSPA5, ERN2 TDP1 25/4885GAA 189/4885MAPT 1487/4885
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME ACHE, CAT, DNPH1 TDP1 4057/4885GAA 2173/4885MAPT 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.